Trueblood Wealth Management LLC Grows Stock Position in Zoetis Inc. (NYSE:ZTS)

Trueblood Wealth Management LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 13.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,689 shares of the company’s stock after buying an additional 562 shares during the quarter. Trueblood Wealth Management LLC’s holdings in Zoetis were worth $764,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new position in shares of Zoetis in the third quarter worth about $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC lifted its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Quarry LP boosted its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 2.0 %

ZTS stock opened at $166.01 on Monday. The company’s 50 day moving average is $170.93 and its 200 day moving average is $179.98. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Sell-side analysts predict that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.